Prescribing Up for Drugs Associated With Falls in Older Adults
Concurrent rise seen in fall-related mortality in older adults in the United States from 1999 to 2017
Musculoskeletal Disorders
Pamrevlumab Fast Tracked for Duchenne Muscular Dystrophy
Pamrevlumab is a first-in-class fully human antibody that works by inhibiting the activity of connective tissue growth factor.
Do Successive Transfers of an Emergency Patient Amount to an EMTALA Violation?
This month we look at a case involving the Emergency Medical Treatment and Labor Act, commonly referred to as EMTALA. EMTALA was enacted by Congress in 1986 as part of the Consolidated Omnibus Budget Reconciliation Act (COBRA) of 1985. The act was designed to prevent hospitals from ‘patient dumping’; transferring uninsured or Medicaid patients to…
AbbVie Seeks Approval of Risankizumab for Psoriatic Arthritis
The application is supported by 2 pivotal phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2.
Experts Address Osteoporosis Therapy and COVID-19 Vaccination
Oral bisphosphonates should be continued without delay; one-week interval recommended between IV bisphosphonate and vaccine
FDA Panel Votes on Tanezumab for Osteoarthritis Pain
Tanezumab is a humanized monoclonal antibody that selectively targets, binds to, and inhibits nerve growth factor.
Rates of Drug Treatment for Osteoporosis Low in the US
Patterns of drug prescribing for the treatment of osteoporosis often do not follow clinical practice guidelines
Guselkumab Benefits Observed Through 2 Years in Psoriatic Arthritis Trial
The DISCOVER-2 study aimed to evaluate multiple clinical outcomes including joint and skin symptoms and radiographic progression in patients with psoriatic arthritis.
Long-Term Data Demonstrate Sustained Efficacy of Risdiplam in Spinal Muscular Atrophy
In Part 2 of the trial, patients 2-25 years of age received either risdiplam for 24 months or placebo for 12 months followed by risdiplam for 12 months.
Zolgensma Benefits Observed in Presymptomatic SMA Patients
The phase 3 SPR1NT trial is an ongoing open-label, single-arm study evaluating onasemnogene in presymptomatic patients (≤6 weeks of age) with a genetic diagnosis of SMA and 2 or 3 copies of survival motor neuron 2 gene.
